Description
Research on China IVD Reagent (In Vitro
Diagnostic Reagent) Industry, 2013-2017” mainly conducts in-depth analysis on
the external environment, market operation, import &export, as well as
other aspects of China’s IVD reagent industry, and also summaries the latest
development state in 2012 of key domestic enterprises, and finally forecasts
the future industrial development. The information can provide investors with
decision-making reference.
To
Read the Complete Report with TOC Visit:
http://www.marketresearchreports.biz/analysis-details/research-on-china-ivd-reagent-in-vitro-diagnostic-reagent-industry-2013-2017
IVD reagent industry is an emerging
industry in China, the start is late and the development is relatively backward
compares with occidental countries. According to the data provided by IVD
Special Committee, there are 300 to 400 IVD reagent manufacturing enterprises
in China, of which, 200 enterprises own above designated scale; however, only
about 20 enterprises have the ability to achieve annual sales income of more
than CNY 100 million; the enterprises are in small scale in general and the
variety is less.
In 2012, the scale of China’s IVD
market has reached CNY 19 billion, of which, the scale of IVD reagent market
was CNY 13.8 billion.
In recent years, China’s IVD reagent
industry has entered the development phase from the introduction stage, and the
market demand increased rapidly; domestic enterprises grasped opportunities by
virtue of the advantages of high performance cost ratio and closer to the local
market, and seized the market share constantly; thus, the market pattern which
was dominated by the imported products is breaking down gradually.
With the strengthening of R&D
investment and the improvement of products quality, a number of local
enterprises with relatively strong strength have appeared in China’s IVD
reagent industry, which concentrated in biochemical, immune and molecular
diagnoses fields, some products have owned the ability to compete with the
international giants.
The state policy encourages the
competitive enterprises to strengthen their strength. In 2013, a series of
policies which target to improve industry standard and threshold will enter the
substantive operation stage, which will accelerate the elimination of small
enterprises and improve the industry concentration ratio, industrial
consolidation is the development trend, and the enterprises with capital,
technology and scale advantages will win gradually.
To
Buy The Copy of This Report Visit
: http://www.marketresearchreports.biz/analysis/172735
In recent years, due to the
continued sluggishness of European and American pharmaceutical market, the
international giants target on the market expansion brought by China’s new
medical reform, and entered China’s market in succession; after the
China-oriented R&D center transfer, these powerful enterprises began to
compete with China’s enterprises in the low and medium-end markets through
mergers, acquisitions, capital increase and production expansion; therefore,
the competitive enterprises in China’s diagnostic reagent subdivided industries
will face more sever competitions.
Contact
M/s Sheela
90 Sate Street, Suite
700
Albany, NY 12207
USA – Canada Toll
Free: 866-997-4948
